Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Olorofim (F901318), a Novel Antifungal Drug, in Human Plasma and Serum.

Müller C, Fietz C, Koehler P, Sibley G, Nforbugwe ACA, Streichert T, Wiesen MHJ.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01356-18. doi: 10.1128/AAC.01356-18. Print 2018 Nov.

PMID:
30150474
2.

Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus.

du Pré S, Beckmann N, Almeida MC, Sibley GEM, Law D, Brand AC, Birch M, Read ND, Oliver JD.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00231-18. doi: 10.1128/AAC.00231-18. Print 2018 Aug.

3.

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.

Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, du Pré S, Livermore J, Bromley MJ, Wiederhold NP, Hope WW, Kennedy AJ, Law D, Birch M.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12809-12814. doi: 10.1073/pnas.1608304113. Epub 2016 Oct 25.

4.

A streamlined failure mode and effects analysis.

Ford EC, Smith K, Terezakis S, Croog V, Gollamudi S, Gage I, Keck J, DeWeese T, Sibley G.

Med Phys. 2014 Jun;41(6):061709. doi: 10.1118/1.4875687.

PMID:
24877804
5.

Comparisons of the responses of anterior and posterior human adult male bladder neck smooth muscle to in vitro stimulation.

Bolton JF, Whittlestone TH, Sibley GN.

BJU Int. 2008 Dec;102(11):1737-42. doi: 10.1111/j.1464-410X.2008.07930.x. Epub 2008 Aug 18.

6.

Closet addiction in fiction: the search for Christiana Evans.

Sibley G.

Soc Hist Alcohol Drugs. 2007 Spring;21(2):183-202.

PMID:
20069747
7.
8.

Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?

Miller KL, Shafman TD, Anscher MS, Zhou SM, Clough RW, Garst JL, Crawford J, Rosenman J, Socinski MA, Blackstock W, Sibley GS, Marks LB.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):64-9.

PMID:
15629595
9.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J; Carolina Conformal Therapy Consortium.

J Clin Oncol. 2004 Nov 1;22(21):4329-40.

PMID:
15514374
10.

Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.

Miller KL, Marks LB, Sibley GS, Clough RW, Garst JL, Crawford J, Shafman TD.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):355-9.

PMID:
12738309
11.

New Fe(III)-mediated radical cascade reactions of cyclopropyl silyl ethers.

Booker-Milburn KI, Jones JL, Sibley GE, Cox R, Meadows J.

Org Lett. 2003 Apr 3;5(7):1107-9.

PMID:
12659585
12.

Reversible hypertension in a young female: ureteric obstruction due to endometriosis.

Aldington S, Gujral S, Sibley GN.

Int J Clin Pract. 2002 Sep;56(7):552-3.

PMID:
12296621
13.
14.

Investigation of upper tracts after resolution of symptoms due to ureteric calculi.

Sells H, Kabala J, Persad RA, Sibley GN.

Eur Urol. 2001 Mar;39(3):250-2.

PMID:
11275713
15.

Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction?

Fan M, Marks LB, Hollis D, Bentel GG, Anscher MS, Sibley G, Coleman RE, Jaszczak RJ, Munley MT.

J Clin Oncol. 2001 Jan 15;19(2):543-50.

PMID:
11208849
16.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Socinski MA, Marks LB, Garst J, Sibley GS, Blackstock W, Turrisi A, Herndon J, Zhou S, Anscher M, Crawford J, Shafman T, Rosenman J.

Oncologist. 2001;6 Suppl 1:20-4.

17.

73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.

Maguire PD, Marks LB, Sibley GS, Herndon JE 2nd, Clough RW, Light KL, Hernando ML, Antoine PA, Anscher MS.

J Clin Oncol. 2001 Feb 1;19(3):705-11.

PMID:
11157021
18.

Routine 3D treatment planning: opportunities, challenges, and hazards.

Marks LB, Bentel G, Light K, Zhou SM, Sibley G, Anscher M.

Oncology (Williston Park). 2000 Aug;14(8):1191-201; discussion 1201, 1205-8.

19.

A new three-dimensional dose distribution reduction scheme for tubular organs.

Zhou SM, Marks LB, Tracton GS, Sibley GS, Light KL, Maguire PD, Anscher MS.

Med Phys. 2000 Aug;27(8):1727-31.

PMID:
10984217
20.

The role of lung perfusion imaging in predicting the direction of radiation-induced changes in pulmonary function tests.

Marks LB, Hollis D, Munley M, Bentel G, Garipagaoglu M, Fan M, Poulson J, Clough R, Sibley G, Coleman RE, Jaszczak R.

Cancer. 2000 May 1;88(9):2135-41.

PMID:
10813726
21.

Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?

Wang LW, Fu XL, Clough R, Sibley G, Fan M, Bentel GC, Marks LB, Anscher MS.

Radiat Res. 2000 Apr;153(4):405-10.

PMID:
10761000
22.

The rationale and use of three-dimensional radiation treatment planning for lung cancer.

Marks LB, Sibley G.

Chest. 1999 Dec;116(6 Suppl):539S-545S. Review.

PMID:
10619527
24.

A neural network to predict symptomatic lung injury.

Munley MT, Lo JY, Sibley GS, Bentel GC, Anscher MS, Marks LB.

Phys Med Biol. 1999 Sep;44(9):2241-9.

PMID:
10495118
25.

The effect of patient-specific factors on radiation-induced regional lung injury.

Garipagaoglu M, Munley MT, Hollis D, Poulson JM, Bentel GC, Sibley G, Anscher MS, Fan M, Jaszczak RJ, Coleman RE, Marks LB.

Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):331-8.

PMID:
10487553
26.

Clinical and dosimetric predictors of radiation-induced esophageal toxicity.

Maguire PD, Sibley GS, Zhou SM, Jamieson TA, Light KL, Antoine PA, Herndon JE 2nd, Anscher MS, Marks LB.

Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):97-103.

PMID:
10477012
27.

Review. The fate of the urethra after definitive treatment of invasive transitional cell carcinoma of the urinary bladder.

Bell CR, Gujral S, Collins CM, Sibley GN, Persad RA.

BJU Int. 1999 Apr;83(6):607-12. Review. No abstract available.

PMID:
10233565
28.

Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects.

Munley MT, Marks LB, Scarfone C, Sibley GS, Patz EF Jr, Turkington TG, Jaszczak RJ, Gilland DR, Anscher MS, Coleman RE.

Lung Cancer. 1999 Feb;23(2):105-14.

PMID:
10217614
29.
31.

Non-painful paraphimosis causing partial amputation.

Hollowood AD, Sibley GN.

Br J Urol. 1997 Dec;80(6):958. No abstract available.

PMID:
9439421
32.

Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.

Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR.

Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):149-54.

PMID:
9422571
33.

Physical and biological predictors of changes in whole-lung function following thoracic irradiation.

Marks LB, Munley MT, Bentel GC, Zhou SM, Hollis D, Scarfone C, Sibley GS, Kong FM, Jirtle R, Jaszczak R, Coleman RE, Tapson V, Anscher M.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):563-70.

PMID:
9336133
34.

Developments in our understanding of detrusor instability.

Sibley GN.

Br J Urol. 1997 Jul;80 Suppl 1:54-61. Review.

PMID:
9240226
35.

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck.

Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW.

Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):285-9.

PMID:
9226314
36.

Alternatives to a urostomy bag.

Sibley GN.

Br J Theatre Nurs. 1996 Jun;6(3):12. No abstract available.

PMID:
8850883
37.

A retrospective study of the investigation and management of muscle-invasive bladder cancer in the South West Region.

Dickinson AJ, Howe K, Bedford C, Sanders T, Prentice A, Sibley GN.

Br J Urol. 1996 Jan;77(1):70-5.

PMID:
8653320
38.

Neuropathic urinary retention in the absence of neurological signs.

Sylvester PA, McLoughlin J, Sibley GN, Dorman PJ, Kabala J, Ormerod IE.

Postgrad Med J. 1995 Dec;71(842):747-8.

39.

The treatment of stage III nonsmall cell lung cancer using high dose conformal radiotherapy.

Sibley GS, Mundt AJ, Shapiro C, Jacobs R, Chen G, Weichselbaum R, Vijayakumar S.

Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1001-7.

PMID:
7493826
40.

Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.

Mundt AJ, Sibley G, Williams S, Hallahan D, Nautiyal J, Weichselbaum RR.

Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):261-70.

PMID:
7673013
41.

Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results.

Mundt AJ, Awan A, Sibley GS, Simon M, Rubin SJ, Samuels B, Wong W, Beckett M, Vijayakumar S, Weichselbaum RR.

Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85.

PMID:
7607972
42.

Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma.

Sibley GS, Mundt AJ, Goldman S, Nachman J, Reft C, Weichselbaum RR, Hallahan DE, Johnson L.

Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1127-35.

PMID:
7607934
43.

An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.

Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL.

J Urol. 1995 Jul;154(1):237-41.

PMID:
7776437
44.

The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors.

Branch RA, Chern HD, Adedoyin A, Romkes-Sparks M, Lesnick TG, Persad R, Wilkinson GR, Fleming CM, Dickinson AJ, Sibley G, et al.

Pharmacogenetics. 1995;5 Spec No:S97-102. Review.

PMID:
7581498
45.

Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas.

Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL.

Br J Urol. 1994 Dec;74(6):762-6.

PMID:
7530131
46.

Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.

Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA.

Carcinogenesis. 1994 Sep;15(9):1955-61.

PMID:
7923590
47.

Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.

Mundt AJ, Sibley GS, Williams S, Rubin SJ, Heimann R, Halpern H, Weichselbaum RR.

Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):151-60.

PMID:
8083108
48.

Seminal vesicle abscess.

Kore RN, McLoughlin J, Kabala J, Sibley GN.

Br J Urol. 1994 Mar;73(3):331-2. No abstract available.

PMID:
8162524
49.

P-glycoprotein expression, tumor differentiation, chemosensitivity of tumor-cells in-vitro and clinical outcome in patients with renal-cell carcinoma.

Lai T, Angus R, Collins C, Feneley R, Sibley G, Smith P, Stonebridge B, Symes M.

Int J Oncol. 1994 Jan;4(1):211-3.

PMID:
21566915
50.

Occult spinal cord injury sustained by high velocity automobile collision.

Gee A, McLoughlin J, Byrnes SM, Sibley GN.

Arch Emerg Med. 1993 Jun;10(2):123-7. No abstract available.

Supplemental Content

Loading ...
Support Center